Lipocine Inc.
LPCN Healthcare Biotechnology
Lipocine Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 82.3% from fiscal 2024. In the quarter to June 2026, revenue fell 69.5%, EPS grew 22.0% and free cash flow fell 60.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow LPCN
Lipocine Inc. (LPCN) EV/Sales
As of 16 October 2026, Lipocine Inc. (LPCN) trades at a EV/Sales of −5.2×. Over the past ten years it has ranged from −5.2× (October 2026) to 25.0× (January 2026) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 16.1× | 2,395.98% |
| FY2024 | 0.6× | (62.55%) |
| FY2023 | 1.7× | 305.57% |
| FY2022 | 0.4× | (84.34%) |
| FY2021 | 2.7× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.4× | (97.28%) |
| Mar 2026 | 16.2× | 1.02% |
| Dec 2025 | 16.1× | 2,055.63% |
| Sep 2025 | 0.7× | 68.42% |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | −66.3× |
| LPCN Lipocine Inc. | −5.2× |
| RVLP RVL Pharmaceuticals PLC compare | 1.0× |
| CLVSQ Clovis Oncology, Inc. compare | 3.1× |
| CNSY Cerenome, Inc. compare | 3.3× |
| ICU SeaStar Medical Holding Corporation compare | 4.4× |
| TVRD Tvardi Therapeutics, Inc. compare | 4.8× |
| BCDA BioCardia, Inc. compare | 30.2× |
| HIND Vyome Holdings, Inc. compare | 139× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)